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Abstract
The purpose of the review is to:
(a) provide information concerning the physiology of lung cancer imaging with fluorodeoxyglucose (FDG) positron
emission tomography (PET);
(b) clarify the role of FDG–PET in the diagnosis of solitary pulmonary nodules;
(c) summarise the accuracy of PET scanning in the staging of lung cancer both in regard to mediastinal nodal
staging and the staging of distant metastases.
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Solitary pulmonary nodules
Positron emission tomography (PET) with F-18 2-fluoro-
2-deoxy-D-glucose (FDG), a glucose analogue labelled
with positron-emitting fluorine-18, is a useful imaging
modality for evaluating patients with lung cancer. Most
malignant tumours are characterised by increased glucose
metabolism. Because tumours are metabolically active,
tumour cells take up increased amounts of FDG relative
to normal lung tissue. FDG is therefore highly sensitive
in the identification of malignant tumours.
PET was previously available only in institutions
with an on-site cyclotron. FDG is now distributed
commercially, and PET imaging for lung cancer has been
approved for reimbursement by most third-party payers.
PET with FDG has become an additional option for
the evaluation of solitary pulmonary nodules and other
focal lung lesions. Reported sensitivities for the detection
of lung cancer have ranged in various reports between
83 and 100%, with specificities of 63–90% using standard
uptake values of equal to or greater than 2.5 [1,2]. False-
negative studies, however, can occur in tumours with low
metabolic activity, such as bronchioloalveolar carcinoma
and carcinoid tumours, and in small nodules that are
smaller than 1 cm in diameter [3,4]. False-positive studies
may occur in benign nodules or lesions with high
metabolic rates, such as active inflammatory processes.
These include infections such as infectious granulomas
and sarcoidosis.
The negative predictive value of a PET study is
clinically useful. Patients with focal lung lesions without
significant FDG uptake can be followed because a
negative finding is highly suggestive of a benign
abnormality. The positive predictive value is lower,
and such lesions frequently require biopsy; however
the positive predictive value for FDG–PET is 90% in
patients over 60 years of age. The FDG–PET scan
should also be interpreted in conjunction with the clinical
likelihood of lung cancer in a given patient and other
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radiologic features of focal lesions, such as growth rate,
morphologic features, and the presence or absence of
contrast enhancement.
Staging of lung cancer
PET has recently proved useful in the staging of lung
carcinoma in the determination of the presence of nodal
disease and distant metastases. In several studies, up to
18% of patients considered to be resectable have more
advanced disease demonstrated by PET imaging.
Regarding nodal staging, the sensitivity of PET
has been reported in the range of 76–100% and
specificities range from 82 to 100%. Several studies
have demonstrated the superiority of FDG–PET over CT
scanning in the evaluation of nodal disease. In a meta-
analysis comparing the value of PET in 514 patients
studied from 1994 to 1998 to CT studies in 2226 patients
studied in the same period, PET was more accurate than
CT in demonstrating nodal metastases from non-small
cell lung cancer. The mean sensitivity and specificity
for PET was 79 and 91%; for CT scanning, it was
60 and 77%. Wahl et al. [5] demonstrated a sensitivity
of 82% and a specificity of 81% for PET in staging
the mediastinum, as compared with a sensitivity of 64%
and a specificity of 44% for CT scanning. The overall
diagnostic accuracy of PET was 92 and 75% for CT
scanning. Peterman et al. [6] studied 102 patients with
non-small cell lung cancer. The sensitivity for PET in the
detection of mediastinal nodal metastases was 91%, with
a specificity of 86%. Despite the superiority of PET over
CT scanning for evaluation of mediastinal adenopathy,
the resolution of PET makes determination of the extent
of the tumour and involvement of individual lymph
node groups difficult. CT is still required for anatomic
correlation, and the combined use of CT scanning and
PET to stage intrathoracic nodal metastases is clinically
useful.
PET seems to improve the non-invasive detection
of extrathoracic disease. Whole-body PET can stage
intrathoracic and extrathoracic disease in a single
examination, and has an overall greater accuracy than
conventional imaging. Whole-body PET can detect
unsuspected extrathoracic metastases in up to 10% of
patients when CT scanning fails to detect them, and may
also alter management in up to 40% of cases.
PET may be used to evaluate adrenal masses, with
sensitivities and specificities of PET reported to be
100% and 80–100% respectively [7]. The bones are
another common site of metastatic disease. PET detects
lesions not found on conventional studies. The accuracy,
sensitivity, and specificity of PET for bone metastases
have been reported to be above 90% [8]. There are,
however, limitations in the PET evaluation of brain
metastases. The normal brain has significant glucose
uptake, and metastases may be difficult to detect on PET.
Reports of low sensitivity (68%) have been reported in
detecting brain metastases, and PET should not be used
to replace CT or MR imaging. There are limitations of
PET in the evaluation of non-small cell lung cancer. The
positive predictive value of PET is lower in patients with
inflammation (e.g. in post-obstructive pneumonia). The
limited anatomic resolution of PET makes evaluation of
the extent of the tumour less reliable than CT scanning or
MR imaging.
Preliminary studies have also demonstrated the benefit
of FDG–PET in measuring response to chemotherapy
and radiation and also in the detection of recurrent
disease [9]. PET has been reported to have a sensitivity of
97–100% and a specificity of 62–100% in the detection
of recurrent tumours. Scans are most reliable 6 months
to 1 year after completion of therapy. Before that time,
hypermetabolic inflammatory changes may result in
false-positive studies.
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